Alan Rembach1, Noel G Faux2, Andrew D Watt2, Kelly K Pertile2, Rebecca L Rumble2, Brett O Trounson2, Christopher J Fowler2, Blaine R Roberts2, Keyla A Perez2, Qiao-Xin Li2, Simon M Laws3, Kevin Taddei3, Stephanie Rainey-Smith3, Joanne S Robertson2, Manu Vandijck4, Hugo Vanderstichele5, Kevin J Barnham2, Kathryn A Ellis6, Cassandra Szoeke7, Lance Macaulay8, Christopher C Rowe9, Victor L Villemagne10, David Ames11, Ralph N Martins3, Ashley I Bush2, Colin L Masters2. 1. The Mental Health Research Institute, The University of Melbourne, Victoria, Australia. Electronic address: a.rembach@unimelb.edu.au. 2. The Mental Health Research Institute, The University of Melbourne, Victoria, Australia. 3. Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital), Perth, Western Australia, Australia; Centre of Excellence for Alzheimer's Disease Research & Care, School of Medical Sciences, Edith Cowan University, Joondalup. Western Australia, Australia. 4. Department of Diagnostic Development, Innogenetics NV, Ghent, Belgium. 5. Department of Diagnostic Development, Innogenetics NV, Ghent, Belgium; Biomarkable, Gent, Belgium. 6. The Mental Health Research Institute, The University of Melbourne, Victoria, Australia; Department of Psychiatry, St George's Hospital, University of Melbourne, Victoria, Australia; National Ageing Research Institute, Parkville, Victoria, Australia. 7. Department of Psychiatry, St George's Hospital, University of Melbourne, Victoria, Australia; National Ageing Research Institute, Parkville, Victoria, Australia. 8. CSIRO Molecular and Health Technologies, Parkville, Victoria, Australia. 9. Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia. 10. The Mental Health Research Institute, The University of Melbourne, Victoria, Australia; Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia. 11. National Ageing Research Institute, Parkville, Victoria, Australia.
Abstract
BACKGROUND: A practical biomarker is required to facilitate the preclinical diagnosis of Alzheimer's disease (AD). METHODS: Plasma amyloid beta (Aβ)1-40, Aβ1-42, Aβn-40, and Aβn-42 peptides were measured at baseline and after 18 months in 771 participants from the Australian Imaging Biomarkers and Lifestyle (AIBL) study of aging. Aβ peptide levels were compared with clinical pathology, neuroimaging and neuropsychological measurements. RESULTS: Although inflammatory and renal function covariates influenced plasma Aβ levels significantly, a decrease in Aβ1-42/Aβ1-40 was observed in patients with AD, and was also inversely correlated with neocortical amyloid burden. During the 18 months, plasma Aβ1-42 decreased in subjects with mild cognitive impairment (MCI) and in those transitioning from healthy to MCI. CONCLUSION: Our findings are consistent with a number of published plasma Aβ studies and, although the prognostic value of individual measures in any given subject is limited, the diagnostic contribution of plasma Aβ may demonstrate utility when combined with a panel of peripheral biomarkers. Crown
BACKGROUND: A practical biomarker is required to facilitate the preclinical diagnosis of Alzheimer's disease (AD). METHODS: Plasma amyloid beta (Aβ)1-40, Aβ1-42, Aβn-40, and Aβn-42 peptides were measured at baseline and after 18 months in 771 participants from the Australian Imaging Biomarkers and Lifestyle (AIBL) study of aging. Aβ peptide levels were compared with clinical pathology, neuroimaging and neuropsychological measurements. RESULTS: Although inflammatory and renal function covariates influenced plasma Aβ levels significantly, a decrease in Aβ1-42/Aβ1-40 was observed in patients with AD, and was also inversely correlated with neocortical amyloid burden. During the 18 months, plasma Aβ1-42 decreased in subjects with mild cognitive impairment (MCI) and in those transitioning from healthy to MCI. CONCLUSION: Our findings are consistent with a number of published plasma Aβ studies and, although the prognostic value of individual measures in any given subject is limited, the diagnostic contribution of plasma Aβ may demonstrate utility when combined with a panel of peripheral biomarkers. Crown
Authors: Alan Rembach; Francesco C Stingo; Christine Peterson; Marina Vannucci; Kim-Anh Do; William J Wilson; S Lance Macaulay; Timothy M Ryan; Ralph N Martins; David Ames; Colin L Masters; James D Doecke Journal: J Alzheimers Dis Date: 2015 Impact factor: 4.472
Authors: Ferenc Deak; Willard M Freeman; Zoltan Ungvari; Anna Csiszar; William E Sonntag Journal: J Gerontol A Biol Sci Med Sci Date: 2015-11-20 Impact factor: 6.053
Authors: Juan Carlos Polanco; Chuanzhou Li; Liviu-Gabriel Bodea; Ramon Martinez-Marmol; Frederic A Meunier; Jürgen Götz Journal: Nat Rev Neurol Date: 2017-12-15 Impact factor: 42.937
Authors: Christopher Fowler; Stephanie R Rainey-Smith; Sabine Bird; Julia Bomke; Pierrick Bourgeat; Belinda M Brown; Samantha C Burnham; Ashley I Bush; Carolyn Chadunow; Steven Collins; James Doecke; Vincent Doré; Kathryn A Ellis; Lis Evered; Amir Fazlollahi; Jurgen Fripp; Samantha L Gardener; Simon Gibson; Robert Grenfell; Elise Harrison; Richard Head; Liang Jin; Adrian Kamer; Fiona Lamb; Nicola T Lautenschlager; Simon M Laws; Qiao-Xin Li; Lucy Lim; Yen Ying Lim; Andrea Louey; S Lance Macaulay; Lucy Mackintosh; Ralph N Martins; Paul Maruff; Colin L Masters; Simon McBride; Lidija Milicic; Madeline Peretti; Kelly Pertile; Tenielle Porter; Morgan Radler; Alan Rembach; Joanne Robertson; Mark Rodrigues; Christopher C Rowe; Rebecca Rumble; Olivier Salvado; Greg Savage; Brendan Silbert; Magdalene Soh; Hamid R Sohrabi; Kevin Taddei; Tania Taddei; Christine Thai; Brett Trounson; Regan Tyrrell; Michael Vacher; Shiji Varghese; Victor L Villemagne; Michael Weinborn; Michael Woodward; Ying Xia; David Ames Journal: J Alzheimers Dis Rep Date: 2021-06-03